Association of American Cancer Institutes

3708 Fifth Avenue
Medical Arts Building, Suite 503
Pittsburgh, PA 15213

Phone: 412-647-6111

www.aaci-cancer.org

Annual Meeting
September 29 – October 1, 2013

CME sponsored jointly by the American Association for Cancer Research and the Association of American Cancer Institutes

Association of American Cancer Institutes
Welcome

The cancer centers represented by the Association of American Cancer Institutes (AACI) form America’s cancer research infrastructure and are the hubs of critical discoveries, treatment advances and improvements in patient care. AACI and the Cancer Center Administrators Forum (CCAF) jointly formulated the program for the 2013 AACI/CCAF Annual Meeting.

This event convenes AACI cancer center directors and executive-level administrators with leaders of national cancer research and advocacy groups, industry, and government health agencies to develop solutions to common challenges and to share best practices. No other program presents information on cancer research and patient care issues as they pertain to the leaders of the nation’s cancer centers, and provides them with a forum to discuss common issues. The gathering also affords an opportunity to acknowledge scientific leaders and individuals in public service who help to advance and promote cancer research.

Meeting sessions will focus in part on the intersection of science and cancer center operations in the areas of precision oncology, the costs of cancer care, drug development, clinical research management, and federal and state support for cancer research.
Program Committee

2013 AACI/CCAF Annual Meeting Program Committee Members

**Chair:** Roy Jensen, MD  
University of Kansas Cancer Center

**Michael Benedict, PharmD**  
Georgia Regents University Cancer Center

**Walter Curran Jr, MD, FACR**  
Winship Cancer Institute of Emory University

**Bob DiPaola, MD**  
The Cancer Institute of New Jersey  
Robert Wood Johnson Medical School

**Chad Ellis, PhD**  
Yale Cancer Center  
Yale University School of Medicine

**Shirley Gray, MA**  
Winthrop P. Rockefeller Cancer Institute  
University of Arkansas for Medical Sciences

**Steve Gruber, MD, PhD, MPH**  
USC/Norris Comprehensive Cancer Center  
University of Southern California

**Michelle M. Le Beau, PhD**  
University of Chicago Comprehensive Cancer Center

**Barbara Duffy Stewart, MPH**  
Association of American Cancer Institutes

**Jeanine Stiles**  
UC Davis Comprehensive Cancer Center  
The University of California, Davis Medical Center

**Jacquie Tidball**  
UCI Chao Family Comprehensive Cancer Center  
University of California at Irvine

**Barbara Vance, PhD, CRA**  
NYU Cancer Institute

**Cheryl Willman, MD**  
University of New Mexico Cancer Center

---

Agenda

**Sunday, September 29**

**11:00 am**  
Registration Begins  
Grand Ballroom Foyer, Ballroom Level

**12:00 pm**  
Exhibits Open  
Grand Ballroom Foyer, Ballroom Level

**12:00 pm**  
Welcome and AACI Business Meeting

- President’s Report  
  Dr. Michelle Le Beau  
  University of Chicago Comprehensive Cancer Center

- Executive Director’s Report  
  Ms. Barbara Duffy Stewart  
  Association of American Cancer Institutes

- Treasurer’s Report  
  Ms. Dorothy Puhy  
  Dana-Farber Cancer Institute

- CCAF Report  
  Ms. Jeanine Stiles  
  UC Davis Comprehensive Cancer Center

- Program Chair’s Report  
  Dr. Roy A. Jensen  
  University of Kansas Cancer Center

**12:45 pm**  
Health Care Reform and the Future of Cancer Care in America  
Dr. Ezekiel Emanuel  
University of Pennsylvania

**1:45 pm**  
States’ Support of Cancer Research  
Ms. Lisa Damiani  
Roswell Park Cancer Institute

- Mr. Ted Yank  
  Dan L. Duncan Cancer Center, Baylor College of Medicine

- Ms. Andrea Brown  
  Blood Research Institute, BloodCenter of Wisconsin

- Ms. Brenda Brito  
  Medical College of Wisconsin Cancer Center

**2:15 pm**  
Break

*Program Subject to Change*
Sunday, September 29 continued

2:30 pm  Concurrent Sessions —

Precision Oncology: Implementation of Molecular Diagnostics and Next-Generation Sequencing
Grand Ballroom C

Moderator:
Dr. Michelle M. Le Beau
University of Chicago
Comprehensive Cancer Center

Expect the Unexpected: Guidance for the New CCSG Guidelines
Grand Ballroom A

Moderator: Ms. Jeanine Stiles
UC Davis Comprehensive Cancer Center

Dr. Scott Lippman
UC San Diego Moores Cancer Center

Dr. Louis M. Weiner
Georgetown Lombardi Comprehensive Cancer Center

Mr. Ira Goodman
UC San Diego Moores Cancer Center

Profile: Personalized Cancer Genetics in Practice
Dr. Neal Lindeman
Harvard Medical School

Bringing Genomics Testing to the Oncology Clinic: Challenges and Rewards
Dr. Gary Palmer
Foundation Medicine, Inc.

Monday, September 30

7:00 am  Continental Breakfast (Oriental Ballroom, Ballroom Level)

7:00 am  Exhibits Open (Grand Ballroom Foyer, Ballroom Level)

8:00 am  Precision Oncology: Social, Ethical, and Legal Considerations

Ethical Discovery and Discernment in Precision Oncology
Moderator: Dr. Colleen Gallagher
MD Anderson Cancer Center

Communication Challenges in Precision Oncology
Dr. Lawrence C. An
University of Michigan Comprehensive Cancer Center

The MedBook Social Network and Knowledge System for Patients, Doctors and Researchers
Dr. Ted Goldstein
University of California Santa Cruz

Balancing the Needs of One Versus the Needs of Many – How Do We Learn More?
Dr. Lee Newcomer
UnitedHealthcare

9:30 am  Health Care Reform and the Nation’s Cancer Centers
The Hon. Kathleen Sebelius
United States Secretary of Health and Human Services

10:00 am  Break

10:15 am  Quality Improvement and Assurance Efforts in Cancer Centers in Europe
Dr. Wim van Harten
Organisation of European Cancer Institutes

10:30 am  2013 AACI Distinguished Scientist Awardee Presentation
Accelerating Progress in Cancer Research
Dr. Brian J. Druker
OHSU Knight Cancer Institute
# Agenda

## Monday, September 30 continued

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 am</td>
<td>Luncheon (Oriental Ballroom, Ballroom Level)</td>
</tr>
<tr>
<td>12:30 pm</td>
<td><strong>Poster Session - AACI Translational Cancer Research Fellows</strong></td>
</tr>
<tr>
<td></td>
<td>(Grand Ballroom Foyer, Ballroom Level)</td>
</tr>
<tr>
<td></td>
<td>Dr. Scott V. Bratman</td>
</tr>
<tr>
<td></td>
<td>Stanford Cancer Institute</td>
</tr>
<tr>
<td></td>
<td>Dr. Shaun Rosebeck</td>
</tr>
<tr>
<td></td>
<td>University of Michigan Health System, University of Chicago</td>
</tr>
<tr>
<td></td>
<td>Dr. Hubing Shi</td>
</tr>
<tr>
<td></td>
<td>David Geffen School of Medicine at UCLA</td>
</tr>
<tr>
<td></td>
<td>Dr. David VanderWeele</td>
</tr>
<tr>
<td></td>
<td>University of Chicago</td>
</tr>
<tr>
<td>1:00 pm</td>
<td><strong>Cost of Cancer Care in the 21st Century</strong></td>
</tr>
<tr>
<td></td>
<td>Moderator: Dr. Ellen V. Sigal</td>
</tr>
<tr>
<td></td>
<td>Friends of Cancer Research</td>
</tr>
<tr>
<td></td>
<td>Do We Need a Different Payment Model for Oncology?</td>
</tr>
<tr>
<td></td>
<td>Dr. Peter Bach</td>
</tr>
<tr>
<td></td>
<td>Memorial Sloan-Kettering Cancer Center</td>
</tr>
<tr>
<td></td>
<td>What is the Financial Impact of Cancer Care Costs on Patients?</td>
</tr>
<tr>
<td></td>
<td>Dr. Scott Ramsey</td>
</tr>
<tr>
<td></td>
<td>Fred Hutchinson Cancer Research Center</td>
</tr>
<tr>
<td></td>
<td>What’s New at CMS</td>
</tr>
<tr>
<td></td>
<td>Dr. Louis Jacques</td>
</tr>
<tr>
<td></td>
<td>Centers for Medicare &amp; Medicaid Services</td>
</tr>
<tr>
<td>2:30 pm</td>
<td><strong>Integrating Cancer Centers and CTSAs</strong></td>
</tr>
<tr>
<td></td>
<td>Moderator: Dr. Roy A. Jensen</td>
</tr>
<tr>
<td></td>
<td>University of Kansas Cancer Center</td>
</tr>
<tr>
<td></td>
<td>Catalyzing Translational Innovation</td>
</tr>
<tr>
<td></td>
<td>Dr. Christopher P. Austin</td>
</tr>
<tr>
<td></td>
<td>National Center for Advancing Translational Sciences</td>
</tr>
<tr>
<td></td>
<td>1 + 1 = 3: Empowering the Case Comprehensive Cancer Center, CWRU CTSC Alignment</td>
</tr>
<tr>
<td></td>
<td>Dr. Stan Gerson</td>
</tr>
<tr>
<td></td>
<td>Case Comprehensive Cancer Center</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>Break</td>
</tr>
<tr>
<td>3:45 pm</td>
<td><strong>Opportunities to Assist Drug Discovery/Development</strong></td>
</tr>
<tr>
<td></td>
<td>Collaborative Drug Discovery and Development Resources at NCATS</td>
</tr>
<tr>
<td></td>
<td>Moderator: Dr. Christopher P. Austin</td>
</tr>
<tr>
<td></td>
<td>National Center for Advancing Translational Sciences</td>
</tr>
<tr>
<td></td>
<td>The Leukemia &amp; Lymphoma Society: Forging Innovative Drug Discovery and Development Partnerships in Areas of High Unmet Medical Need</td>
</tr>
<tr>
<td></td>
<td>Dr. Mark Velleca</td>
</tr>
<tr>
<td></td>
<td>Leukemia and Lymphoma Society</td>
</tr>
<tr>
<td></td>
<td>The Learning Collaborative — A Unique Partnership to Discover and Develop New Treatments for Blood Cancers</td>
</tr>
<tr>
<td></td>
<td>Dr. Scott Weir</td>
</tr>
<tr>
<td></td>
<td>University of Kansas Cancer Center</td>
</tr>
<tr>
<td></td>
<td>Johnson &amp; Johnson Innovation Centers: New Approaches to Collaborations with Academia</td>
</tr>
<tr>
<td></td>
<td>Dr. William N. Hait</td>
</tr>
<tr>
<td></td>
<td>Janssen Research &amp; Development, LLC</td>
</tr>
<tr>
<td>5:15 pm</td>
<td>NCI Office of Cancer Centers Update</td>
</tr>
<tr>
<td></td>
<td>Dr. Linda K. Weiss</td>
</tr>
<tr>
<td></td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>6:15 pm</td>
<td>Adjourn</td>
</tr>
<tr>
<td>8:30 pm</td>
<td><strong>Hospitality Suite</strong> (Garden 1 – Lobby Level)**</td>
</tr>
</tbody>
</table>

## Tuesday, October 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am</td>
<td><strong>Continental Breakfast</strong> (Oriental Ballroom, Ballroom Level)**</td>
</tr>
<tr>
<td>7:30 am</td>
<td><strong>Exhibits Open</strong> (Grand Ballroom Foyer, Ballroom Level)**</td>
</tr>
</tbody>
</table>
Agenda

Tuesday, October 1 continued

7:30 am  Topic Specific Roundtables  (Freer and Portrait, Ballroom Level)

9:00 am  NCI Support for Clinical Research
Dr. Jeffrey S. Abrams
Cancer Therapy Evaluation Program, National Cancer Institute

9:30 am  Break

9:45 am  AACI Public Service Award Presentations
2013 AACI Distinguished Public Service Award
Rep. Lois Capps (D-CA)
2013 AACI Distinguished Public Service Award
Rep. Peter T. King (R-NY)

10:15 am  AACI Clinical Research Initiative: Optimizing Clinical Research Management
The Right Drug for the Right Patient: Optimizing Clinical Trials Management
Moderator: Dr. Tony R. Reid
UC San Diego Moores Cancer Center
Considerations for Management of Multi-Center Studies
Ms. Elizabeth Anderson
OHSU Knight Cancer Institute
Ms. Rhoda Arzoomanian
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
Funding Challenges of a Clinical Trials Office
Dr. Kirsten Erickson
The University of Kansas Cancer Center
The Changing Environment and the Impact on Clinical Research
Dr. Michael Benedict
Georgia Regents University Cancer Center
Physician Engagement: Developing Clinical Research Incentives for Academic Oncologists
Dr. Randy F. Holcombe
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

11:45 am  Adjourn

Continuing Medical Education

Joint Sponsorship Statement
Jointly sponsored by the American Association for Cancer Research and the Association of American Cancer Institutes.

Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the American Association for Cancer Research and the Association of American Cancer Institutes. The American Association for Cancer Research is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The American Association for Cancer Research designates this live activity for a maximum of 13.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Learning Objectives
Physicians and other health care professionals who attend the meeting should be able to summarize the program content, discuss its application in clinical practice, and convey the information to administrators at their centers. As part of the program’s learning objectives, all attendees should be able to describe and discuss:

- The delivery of effective precision oncology.
- Compliance with NCI’s new guidelines for the Cancer Center Support Group (CCSG) award.
- The financial, ethical, and legal impact of molecular diagnostics and precision oncology on cancer center daily operations.
- The challenges and opportunities associated with delivering personalized medicine in underserved populations.
- New insights about the most effective treatments for patients whose leukemia recurs while taking a targeted therapy drug.
- Optimal deployment of infrastructure resources made available to academic institutions via the Clinical and Translational Science Award (CTSA) and Cancer Center Support Grant (CCSG) mechanisms.
- Opportunities, obligations and challenges associated with establishing cancer center and industry collaborations regarding drug development.
- Benefits to cancer patients of the NCI Cancer Therapy Evaluation Program (CTEP).
- The effectiveness of a multi-disciplinary environment in facilitating translational medicine.
- NCI’s programmatic priorities, policies, strategies and goals for the national cancer research enterprise, and their relationship to the nation’s cancer centers.
Americans with Disabilities Act
It is the policy of American Association for Cancer Research not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please contact Sara Arvay at 412-605-1476 or attach a note to your registration form.

Faculty Disclosure
It is the policy of the American Association for Cancer Research and the Association of American Cancer Institutes to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

Target Audience
This trans-disciplinary conference is designed for basic and clinical scientists, as well as for physician-scientists from academia, industry, government, and other institutions with interest in innovative systems and technologies for diagnosing, preventing, and treating cancer and its long-term effects.

Leaders of AACI’s 95 academic and freestanding cancer research centers, including cancer center directors, executive administrators, and other top scientific and clinical leaders—leaders from industry and government agencies as well as those of cancer research and advocacy organizations attend the meeting. All attendees have a significant impact on cancer research and patient care in the U.S. Meeting attendees include medical professionals from across the country, such as oncologists, pharmacists, radiologists, nuclear medicine physicians, nurses, social workers, psychologists, cancer communication specialists, public health leaders, and other faculty members who focus on cancer.

Speakers

Jeffrey S. Abrams, MD
Associate Director
Cancer Therapy Evaluation Program
National Cancer Institute

Dr. Abrams is currently the Acting Director for Clinical Research in the Division of Cancer Treatment and Diagnosis (DCTD) at NCI and also is Associate Director of the Cancer Therapy Evaluation Program (CTEP). After completing his medical oncology fellowship (University of Maryland, 1984), Dr. Abrams joined the University of Maryland faculty from 1985-1992 where he directed their Breast Cancer Evaluation Program and was Associate Professor of Medicine and Oncology.

In 1993, Dr. Abrams joined NCI and was responsible for managing the breast cancer treatment trials portfolio for CTEP. In 2004, he was appointed Chief of the Clinical Investigations Branch which directs the NCI-supported Clinical Trials Cooperative Group program. In 2008, Dr. Abrams became Associate Director of CTEP, DCTD and more recently, in 2010, was named Acting Director for Clinical Research, DCTD. Dr. Abrams is responsible for leading a broad, multidisciplinary clinical research effort to coordinate a nationwide, and international, phase 1-3 clinical trials program testing new treatment approaches for cancer. Dr. Abrams has authored over 80 original publications in the field of breast cancer and clinical trials in general.

Lawrence C. An, MD
Professor of Internal Medicine
University of Michigan Comprehensive Cancer Center

Dr. An is the Director of the Center for Health Communications Research (CHCR). In this role, Dr. An oversees the multidisciplinary CHCR team and has led development of over thirty computer tailored health programs in the past three years. Dr. An did his medical training and internal medicine residency at the University of Michigan before completing fellowships with the Robert Wood Johnson Clinical Scholar’s program and the Agency Health Care Research and Quality.

For 11 years prior to joining the University of Michigan faculty, Dr. An was on faculty at the University of Minnesota where he worked closely with health plans, health care provider organizations, and the state health department. Dr. An’s research teams have developed and tested several web-based tailored interventions for health behavior change. His research has focused primarily on tobacco control in the areas of clinical guideline implementation and health systems change, design and evaluation of statewide tobacco cessation services, and development of innovative web-based and mobile interventions.
**Elizabeth Anderson, MPH, BSN**  
**Director, Clinical Trials Office**  
**Knight Cancer Institute**  
**Oregon Health and Science University**

Ms. Anderson is the Director of the Clinical Trials Office at the Oregon Health and Science University Knight Cancer Institute. She has more than 16 years of clinical research management experience with a particular focus on the management of oncology clinical trials. She has held roles of increasing responsibility in the field of clinical research starting with study coordination and study monitoring, followed by study management and most recently global clinical operations program management for a large program with activities from Phase I through to post-approval commitments. Additional roles have included scientific, operational, personnel and financial management responsibilities for clinical trials.

In her previous positions, Ms. Anderson has been responsible for direct communication regarding operational issues with regulatory agencies in various countries including United States, Europe, China and Japan. She currently oversees the Knight Cancer Institute-wide clinical research management including protocol review and monitoring, data and safety monitoring and study coordination activities for oncology clinical research studies. Ms. Anderson serves as a AACI Clinical Research Initiative Special Interest Group leader for the Industry, Academia and Government Relations SIG.

**Rhoda Arzoomanian, MSM, RN, BSN**  
**Associate Director, Administration**  
**Paul P. Carbone Comprehensive Cancer Center**

Rhoda Arzoomanian is the Associate Director of Administration at the University of Wisconsin Carbone Comprehensive Cancer Center (UWCCC). Ms. Arzoomanian oversees all administrative activities of the UWCCC with direct reporting to the cancer center director. Ms. Arzoomanian joined the UWCCC as a Research Nurse in the Phase I Clinical Research Office in 1988. In the early 1990s, she assumed the role of Program Manager of the Phase I and Genitourinary Clinical Research Programs. In 2001, she was appointed as the Assistant Director of Clinical Research and in 2010 she was appointed to her current role as Associate Director of Administration. Ms. Arzoomanian graduated from Marquette University with a Bachelors of Science in Nursing degree and received a Masters in Business Management from Cardinal Stritch University. For many years, she has represented the UWCCC on numerous national Steering Committees and Special Interest Groups.

**Christopher P. Austin, MD**  
**Director, National Center for Advancing Translational Sciences**  
**National Institutes of Health**

Dr. Austin is Director of the National Center for Advancing Translational Sciences (NCATS) at the U.S. National Institutes of Health. NCATS’ mission is to catalyze the generation of innovative methods and technologies that will enhance the development, testing, and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. Before becoming NCATS Director in September 2012, he was director of the NCATS Division of Preclinical Innovation, which focuses on translating basic science discoveries into new treatments, particularly for rare and neglected diseases, and developing new technologies and paradigms to improve the efficiency of therapeutic and diagnostic development. In this role, he founded and directed numerous initiatives including the NIH Chemical Genomics Center (NCGC), the Therapeutics for Rare and Neglected Diseases (TRND) program, and the Toxicology in the 21st Century (Tox21) program. Before joining NIH in 2002, Dr. Austin directed research programs, genomics-based target discovery, pharmacogenomics, and neuropsychiatric drug development at Merck, with a particular focus on schizophrenia.

**Peter Bach, MD, MAPP**  
**Director, Center for Health Policy and Outcomes**  
**Epidemiology and Biostatics Department**  
**Memorial Sloan-Kettering Cancer Center**

Dr. Bach’s main research interests cover healthcare policy, particularly as relates to Medicare, racial disparities in cancer care quality, and lung cancer epidemiology. His research examining quality of care for Medicare beneficiaries has demonstrated that blacks do not receive as high quality care as whites when diagnosed with lung cancer, and that the aptitude and resources of primary care physicians who treat blacks are inferior, when compared to primary care physicians who primarily treat whites.

In 2007 Dr. Bach was the senior author on a study demonstrating that care in Medicare is highly fragmented, with the average beneficiary seeing multiple primary care physicians and specialists. His work in lung cancer epidemiology has focused on the development and utilization of lung cancer prediction models that can be used to determine what lung cancer events populations of elderly smokers will experience over a period of time. His healthcare policy analysis includes investigations into Medicare’s approaches to cancer care payment, as well as developing models of alternative reimbursement, payment systems, and coverage policies.

Dr. Bach is funded by grants from the National Institute of Aging, a contract from the NCI, and philanthropic sources. He formerly served a Senior Advisor to the Administrator of the Centers for Medicare and Medicaid Services, and serves on
several national committees, including the Institute of Medicine’s National Cancer Policy Forum, and the Committee on Performance Measurement of the National Committee on Quality Assurance. He chairs the Technical Expert Panel that is developing measures of cancer care quality for CMS. Along with publishing in the medical literature, Dr. Bach’s opinion pieces have appeared in The New York Times, The Wall Street Journal and on National Public Radio.

**Michael K. Benedict, PharmD**
**Associate Center Director for Administration**
**Georgia Regents University Cancer Center**

Dr. Michael Benedict has over twenty years of progressive experience in developing and managing research infrastructure for nationally recognized cancer centers. Most recently he worked as the Associate Center Director for Research Administration and Vice President for Research Operations at the H. Lee Moffitt Cancer Center and Research Institute.

In addition to his experience at Moffitt, Dr. Benedict has served as Executive Director for Research at Children’s Hospital & Health Center in San Diego, and as Associate Director for Administration at the City of Hope National Medical Center/Beckman Research Institute in Duarte, California. Dr. Benedict’s responsibilities included providing high-level support and day-to-day oversight of clinical research operations including project activation, IND development, and the biorepository.

Dr. Benedict has served as an ad hoc reviewer for the NCI for Cancer Center Support Grants, special translational award programs and the SBIR program.

**Scott V. Bratman, PhD**
**Resident and Postdoctoral Fellow, Department of Radiation Oncology**
**Stanford Cancer Institute**

Dr. Bratman graduated magna cum laude from Princeton University before undertaking his graduate training at Columbia University in New York. He studied basic mechanisms of cell division in the lab of Dr. Fred Chang and obtained his MD and PhD degrees in 2009. He then returned to California for residency in radiation oncology at the Stanford Cancer Institute. While at Stanford he was accepted into the American Board of Radiology's Holman Research Pathway, which has provided him with extended dedicated research time during residency. He joined the lab of Dr. Max Diehn, where he has initiated research projects on breast cancer stem cells and lung cancer biomarkers. He is the recipient of two Resident Research Seed Grants from the Radiological Society of North America for this work.

**Brenda Brito, BSBA**
**Interim Associate Director for Administration**
**Medical College of Wisconsin Cancer Center**

Ms. Brito is currently the interim Associate Director for Administration for the Medical College of Wisconsin (MCW) Cancer Center and has served as Business Manager for the MCW Cancer Center and Clinical Trials Office since 2011. She has more than 17 years of experience in non-profit administration, fiscal oversight and accountability, and currently oversees the financial operation for the MCW Cancer Center including the financial portfolio of clinical trials. Ms. Brito joined the Medical College in 2006 as Department Administrator for Pharmacology & Toxicology and Neuroscience Center. Her prior experience includes 8 years as Associate Director and Fiscal Officer of Spotted Eagle, Inc.

**Andrea Scott Brown, MBA**
**Director of Research Administration**
**Blood Research Institute, BloodCenter of Wisconsin**

Ms. Brown is a senior administrator with more than 16 years of progressive management experience, and more than 10 years of experience within Cancer Center central administration. She has been the Associate Director of Administration for the Medical College of Wisconsin Cancer Center (MCW) for the last three years. Prior to this position she was the Assistant Director of Administration at the Medical University of South Carolina (MUSC). During her career she has worked with two cancer centers that successfully submitted Cancer Center Support Grants to become NCI-designated centers—Hollings Cancer Center at MUSC and Siteman Cancer Center at Washington University School of Medicine in St. Louis—and is working with senior leadership at MCW to do the same.

**Lisa A. Damiani**
**Vice President, External Affairs**
**Roswell Park Cancer Institute**

Lisa Damiani joined the administration of Roswell Park Cancer Institute in 2001 as Executive Director for Governmental Affairs and now serves as the Vice President of External Affairs at the Institute. She acts as Roswell Park’s liaison to elected officials and government agencies, monitors federal and state legislative activities, represents Roswell interests to legislators, and provides recommendations to the Roswell Park administration regarding legislative initiatives. Before joining Roswell Park, Ms. Damiani had extensive experience within New York State Government holding positions within the Attorney General’s Office, the New York State Assembly and as Director of Operations at a state agency whose purpose was to invest in academic research.
Ms. Damiani is the current Chair of AACI’s Government Relations Forum. In 2011, as a representative of Roswell Park, Ms. Damiani participated with a coalition of cancer advocates in successfully advocating for the passage of New York State legislation that equals the out-of-pocket expenses for cancer patients on oral chemotherapy.

Ralph W. deVere White, MD
Director
UC Davis Comprehensive Cancer Center

Dr. W. deVere White is a Distinguished Professor of Urology and Associate Dean for Cancer Programs at UC Davis School of Medicine and Medical Center. He is director of the UC Davis Comprehensive Cancer Center. With more than $2 million in research funding this year, Dr. deVere White is investigating the genetic mistakes that give rise to prostate cancer, the biomolecular mechanisms that make some prostate cancers more virulent than others, and new methods of diagnosing and treating prostate cancer. His most recent research involves the microenvironment and targeting miRNAs.

He has authored more than 300 peer-reviewed scientific articles and book chapters and edited three medical textbooks. He serves on the editorial boards of six international scientific journals. Among his many honors and awards, Dr. deVere White is a member of the Clinical Society of Genitourinary Surgeons. Surgeons are elected into this professional organization based on their outstanding contributions to urology. The highly selective society has only 25 members. Dr. deVere White is one of four urologists serving as a volunteer consultant to the American Cancer Society’s on-line “Experts Answers” bulletin board for questions about prostate cancer.

Brian J. Druker, MD
Director, Knight Cancer Institute
Oregon Health and Science University

Dr. Druker is Director of the OHSU Knight Cancer Institute, Associate Dean for Oncology of the OHSU School of Medicine, JELD-WEN Chair of Leukemia Research at Oregon Health & Science University, and Investigator of the Howard Hughes Medical Institute. Upon graduating from the University of California, San Diego School of Medicine in 1981, Dr. Druker completed his internship and residency in internal medicine at Barnes Hospital, Washington School of Medicine in St. Louis, Missouri. He then trained in oncology at Harvard’s Dana-Farber Cancer Institute. Dr. Druker then returned to the lab to begin his research career studying the regulation of the growth of cancer cells and the practical application to cancer therapies. He developed 4G10, an anti-phosphotyrosine antibody that was an essential reagent to scientists at Novartis in their kinase inhibitor drug discovery program.

In collaboration with Novartis, his laboratory performed pre-clinical studies that were instrumental in the development of Gleevec (imatinib), a drug that targets the molecular defect in chronic myeloid leukemia (CML). After completing a series of preclinical studies, Dr. Druker spearheaded the highly successful clinical trials of imatinib for CML. Imatinib is currently FDA approved for CML, gastrointestinal stromal tumors (GIST) and eight other cancers.

His role in the development of imatinib and its application in the clinic have resulted in numerous awards for Dr. Druker, including the AACR-Richard and Hinda Rosenthal Award, the Warren Alpert Prize from Harvard Medical School, the American Society of Hematology’s Dameshek Prize, the Lance Armstrong Foundation’s Pioneer of Survivorship Carpe Diem Award, the American Cancer Society’s Medal of Honor, the Kettering Prize from General Motors Cancer Research Foundation, the David A. Karnofsky Award from the American Society of Clinical Oncology, the Robert-Koch Award, the 2009 Lasker-DeBakey Award for Clinical Medical Research, the Stanley J. Korsmeyer award from the American Society for Clinical Investigation, the American Society of Hematology’s Ernest Beutler Prize, and the Japan Prize in Healthcare and Medical Technology. He was elected to the Institute of Medicine of the National Academies in 2003, the American Association of Physicians in 2006, the National Academy of Sciences in 2007, and the American Academy of Arts and Sciences in 2012.

Ezekiel Emanuel, MSC, MD, PhD
Diane v.S. Levy and Robert M. Levy University Professor Medical Ethics and Health Policy
University Of Pennsylvania

Dr. Emanuel is the Vice Provost for Global Initiatives, the Diane v.S. Levy and Robert M. Levy University Professor, and Chair of the Department of Medical Ethics and Health Policy at the University of Pennsylvania. He is also an Op-Ed contributor to the New York Times. He was the founding chair of the Department of Bioethics at the National Institutes of Health and held that position until August of 2011. Until January 2011, he served as a Special Advisor on Health Policy to the Director of the Office of Management and Budget and National Economic Council. He is also a breast oncologist and author.

After completing Amherst College, Dr. Emanuel received his MSc from Oxford University in Biochemistry. He received his MD from Harvard Medical School and his PhD in political philosophy from Harvard University. His dissertation received the Toppan Award for the finest political science dissertation of the year. In 1987-88, he was a fellow in the Program in Ethics and the Professions at the Kennedy School of Government at Harvard. After completing his internship and residency in internal medicine at Boston’s Beth Israel Hospital and his oncology fellowship at the Dana-Farber Cancer Institute, he joined the faculty at the Dana-Farber Cancer Institute. Dr. Emanuel was an Associate Professor at Harvard Medical School before joining the National Institutes of Health.
Dr. Emanuel has authored and co-edited 9 books. His most recent book, Brothers Emanuel: A Memoir of An American Family, was released in March, 2013. Other publications include The Oxford Textbook of Clinical Research Ethics, edited by Dr. Emanuel and members of the NIH Department of Bioethics and Healthcare, Guaranteed, Dr. Emanuel's own recommendations for health care reform. Dr. Emanuel also developed The Medical Directive, a comprehensive living will that has been endorsed by Consumer Reports on Health, Harvard Health Letter, the New York Times, Wall Street Journal, and many other publications.

Dr. Emanuel served on President Clinton’s Health Care Task Force, the National Bioethics Advisory Commission (NBAC), and on the bioethics panel of the Pan-American Healthcare Organization. He has received numerous awards including election to the Institute of Medicine (IOM) of the National Academy of Science, the Association of American Physicians, and the Royal College of Medicine (UK).

Kirsten Erickson, PhD
Senior Director Clinical Research Office
The University of Kansas Cancer Center

Dr. Erickson currently serves as the Senior Director of the Clinical Research Office at the University of Kansas Cancer Center. Prior to this, Kirsten served at the University of California, San Diego, Rebecca and John Moores Cancer Center where she served as the Assistant Director of the Clinical Trials Office for 6 years. In both of these roles, Kirsten has managed complex, multi-site, clinical trials programs where she and her teams have developed innovative clinical trials start-up processes and have advanced the clinical trials management systems to achieve the successful activation and completion of clinical trials. Kirsten received her MPH in Epidemiology/Biostatistics in 2004 and her PhD in the same field in 2011. One of Kirsten’s favorite quotes she often employs as a strategic philosophy in optimizing clinical research management comes from Charles Darwin, “It is not the strongest, nor the most intelligent that survive, rather it is the most adaptive to change”.

Colleen M. Gallagher, PhD, MA, LSW, FACHE
Executive Director and Chief of the Section of Integrated Ethics
MD Anderson Cancer Center

Dr. Gallagher is the Executive Director and Chief of the Section of Integrated Ethics in the Division of Medical Affairs and Associate Professor in the Department of Critical Care at The University of Texas MD Anderson Cancer Center. With a focus on the human elements of patient care, Dr. Gallagher applies her knowledge of health care ethics, compassion, communication and mediation to the goals of care for patients. Her research and clinical work in this area focuses on the assessment and management of ethical issues concerning patients with complex symptom problems from the time of diagnosis, through treatment, during survivorship and at the end of life. She works with patients, their family members, faculty, nurses, social workers, chaplains, patient advocates, etc. to ensure best possible outcomes are reached for everyone involved.

Dr. Gallagher is a national leader in health care ethics. She has worked in the fields of social work and health care ethics since 1985. As the Section Chief of Integrated Ethics, Dr. Gallagher oversees a network of clinical rounds, clinical and research consultations and ethics education. She has authored and co-authored peer-reviewed articles and book chapters, and made presentations on a broad range of topics in the field of health care ethics. She holds appointments on various national and international committees, including Food and Drug Administration Molecular Devices Committee, International Ethics Expert for both UNESCO Chair in Science and Technology and UNESCO Chair in Bioethics and Human Rights. She has also served as Ethicist for the Healthcare Quality Professional Task Team of the National Association for Healthcare Quality and Co-Chair of Clinical Ethics Consultation Affairs Committee for the American Society of Bioethics and Humanities (ASBH). Dr. Gallagher is a member of the ASBH Mentor Taskforce and is judge for Bioethics Global Art.

Stanton L. Gerson, MD
Director, Case Comprehensive Cancer Center
Case Western Reserve University
Ireland Cancer Center at University Hospitals of Cleveland

Dr. Gerson is the Asa and Patricia Shiverick- Jane Shiverick (Tripp) Professor of Hematological Oncology, Director NCI designated Case Comprehensive Cancer Center, Director of the Seidman Cancer Center, and founding director of the National Center for Regenerative Medicine in Cleveland.

Dr. Gerson discovered that the MGMT DNA repair gene protected multiple organs from alkylating agent induced malignancies. Later, this discovery was also the basis for development of a drug to block MGMT for cancer treatment, and an MGMT gene therapy approach, currently used in glioma, to protect marrow from chemotherapy. In his stem cell research, he developed mesenchymal stem cells (MSCs) as a therapeutic infusion for blood stem cell transplantation and for the correction of genetic disorders. This therapy has received Canadian Regulatory approval. Dr. Gerson also discovered the use of methoxyamine as a drug to block base excision repair, and identified its potentiation of anti-cancer efficacy when used in combination with either temozolomide, fludarabine or pemetrexed. Each of these is now in cancer clinical trial and is being evaluated at NCI. Finally, Dr. Gerson has developed transgenic mouse models that examine the role of critical DNA repair genes (MGMT, MMR genes, NHEJ genes, and Homologous recombination genes) in the stability of stem cell populations over the lifetime of the animal. These studies may predict stem cell diseases of aging and cancer.
His research has generated 16 patents in the area of gene therapy and cancer drug development that have been licensed to 3 companies. In 2012 he was the recipient of the CWRU Medal for Excellence in Health Science Innovation Award.

Since 2003, Dr. Gerson’s leadership of the National Center of Regenerative Medicine and the Case Comprehensive Cancer Center has involved coordinating research throughout the medical centers in Cleveland – University Hospitals, Cleveland Clinic and Case Western Reserve University. At University Hospitals, he led effort to bring cancer care under one roof in the Seidman Cancer Center hospital that opened in 2011.

Ted Goldstein, PhD
Researcher
Center for Biomolecular Science and Engineering
University of California, Santa Cruz

Dr. Goldstein is a researcher on the SU2C/PCF West Coast Prostate Cancer Dream Team at UCSC, where he is developing MedBook, a social network and bioinformatic system that will unify cancer patients, doctors, clinical and academic researchers in the war against cancer. He is also Director of Research at Guttman Initiatives, a philanthropic development and design firm where he advises on the development of predictive bioinformatic systems for chronic and transitional-care patient monitoring systems. Dr. Goldstein was previously a Vice President of Developer Tools at Apple, Inc. His team created the Mac OS X and iOS runtime systems and the Xcode developer tools for Apple’s Intel, iPhone, and iPad products. Prior to Apple, Dr. Goldstein led the electronic commerce and smart card efforts at Sun Microsystems, where he created Java Card which is used for ecommerce, federal identification and medical information. He holds ten patents in these areas.

Ira S. Goodman, MPA, MS
Associate Director for Administration
UC San Diego Moores Cancer Center

Ira Goodman is the Associate Director for Administration at UC San Diego Moores Cancer Center. He has been in departmental, central administration and research center positions at New York University and University of California San Diego. He has directed and been a member of the Institutional Review Board, the Institutional Animal Care and Use Committee and the Institutional Biosafety Committee. Mr. Goodman has been an NIH study section member and participated in multiple site visits for the NIH. He holds a BS in Biology and Chemistry from LIU; MS in Clinical Management and MPA in Non-Profit Management from the NYU Graduate School of Public Administration, as well as a Certification in Research Administration. Mr. Goodman has written and presented extensively on cancer centers and research administration. He received the Journal of Research Administration Rod Rose Award for best publication, Enhancing Communication in a Multi Campus Research Center.

William N. Hait, MD, PhD
Global Head, Research and Development
Janssen Research & Development, LLC

Dr. Hait is Global Head, Janssen Research & Development, LLC, the global research and development arm of Janssen, the pharmaceutical companies of Johnson & Johnson. In this role, he leads the global R&D group in its mission to develop innovative new medicines to address the world’s most serious unmet medical needs.

Dr. Hait joined Johnson & Johnson in 2007 as Senior Vice President, Worldwide Head of Hematology and Oncology, Ortho Biotech Oncology R&D, and assumed the role of Global TA Head, Oncology, in 2009. Prior to joining Johnson & Johnson, he was the founding Director of The Cancer Institute of New Jersey and Professor of Medicine and Pharmacology and Associate Dean for Oncology Programs at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School from January 1993 to March 2007. Under Dr. Hait’s leadership, The Cancer Institute of New Jersey was successful in obtaining cancer center designation from the National Cancer Institute in 1996 and received the National Cancer Institute’s highest designation of Comprehensive Cancer Center in 2002.

Dr. Hait joined the Yale University School of Medicine faculty in 1984 and was quickly promoted to Associate Professor of Medicine and Pharmacology and Chief of the Division of Medical Oncology and Associate Director of the Yale University Comprehensive Cancer Center. He also served as Director of the Breast Cancer Unit and Co-Director of the Lung Cancer Unit at the Yale University School of Medicine. Dr. Hait is Board Certified in Internal Medicine and Medical Oncology.

Dr. Hait has served on various committees for the American Association for Cancer Research (Chair, Clinical Cancer Research Committee), American Society of Clinical Oncology, AACI (Board of Directors), and the National Cancer Institute Board of Scientific Advisors. He was President of the American Association for Cancer Research from 2007 – 2008, and is currently its Treasurer.

Jay L. Hess, MD, PhD, MHSA
Vice President for University Clinical Affairs
Dean
Indiana University School of Medicine

Dr. Hess recently assumed the roles of the Vice President for University Clinical Affairs and Dean of the School of Medicine at Indiana University. Before joining Indiana, he was the Carl Weller Professor and Chair of the Department of Pathology at the University of Michigan. He has also served as Director of Hematopathology at the University of Pennsylvania and as Assistant Professor of Pathology at Washington University School of Medicine. Dr. Hess received a BA
Speakers

Randall F. Holcombe, MD
Professor of Medicine, Division of Hematology and Medical Oncology
Mount Sinai School of Medicine
Director, Clinical Cancer Affairs, Mount Sinai Medical Center
Deputy Director, Tisch Cancer Institute

Dr. Holcombe is Professor of Medicine, Division of Hematology and Medical Oncology at Mount Sinai School of Medicine, Director of Clinical Cancer Affairs for Mount Sinai Medical Center, and Deputy Director of the Tisch Cancer Institute. He has had extensive experience over the past 20 years in translational research and the conduct of oncology clinical trials. His research activities are focused on clinical research for patients with colorectal cancer and other GI malignancies and laboratory studies involving signaling pathways in the colon tumor microenvironment and the role of natural products in modulating cancer biology and anti-cancer host immune responses. His research has been funded by the NIH and multiple foundations and has resulted in more than 85 peer-reviewed manuscript publications and more than 180 published conference abstracts.

Dr. Holcombe has extensive expertise in the conduct and regulatory aspects of clinical and translational research. In his past position at the University of California, Irvine he served as Associate Director for Clinical Research for the NCI-designated Comprehensive Cancer Center, established an Office of Clinical Research and Trials for the School of Medicine, and served as Associate Vice Chancellor for Research, a position which involved oversight of all research regulatory and compliance committees for the University.

Louis B. Jacques, MD
Director, Coverage & Analysis Group
Centers for Medicare & Medicaid Services

Dr. Jacques joined CMS in 2003 and has been director of the Coverage and Analysis Group (CAG) since October 2009. The group reviews evidence and develops Medicare national coverage policy. CAG is also the lead CMS component on Coverage with Evidence Development (CED) and the FDA CMS Parallel Review initiative. From 2004 through 2009 he was Director of the Division of Items and Devices within CAG.

Prior to his arrival at CMS, Dr. Jacques was the Associate Dean for Curriculum at Georgetown University School of Medicine. There, he served on a number of university committees including the Executive Faculty, Committee on Admissions and the Institutional Review Board. Dr. Jacques also worked in the Palliative Care program at Georgetown’s Lombardi Comprehensive Cancer Center where he covered the gynecologic oncology service and he made home visits as a volunteer physician for a hospice on the Maryland Eastern Shore. He began his postgraduate clinical career in 1985 as a National Health Service Corps physician in a Waterloo, Iowa community health clinic.

Roy A. Jensen, MD
Director, The University of Kansas Cancer Center
Director, Kansas Masonic Cancer Research Institute

Dr. Jensen was born in Kansas City, Kansas and earned his bachelor’s degree in Biology and Chemistry from Pittsburg State University in 1980. He graduated from Vanderbilt University School of Medicine in 1984, and remained there to complete a residency in Anatomic Pathology and a Surgical Pathology fellowship under the direction of Dr. David L. Page. Following his clinical training he accepted a Biotechnology Training fellowship at the National Cancer Institute in the laboratory of Dr. Stuart Aaronson. He returned to Vanderbilt in 1991 and was appointed an Assistant Professor in the Departments of Pathology and Cell Biology. In 1993 Dr. Jensen was appointed as an investigator in the Vanderbilt-Ingram Cancer Center and assumed the management of the Human Tissue Acquisition and Pathology Shared Resource. Dr. Jensen was promoted to Associate Professor of Pathology and Cell Biology in 1996, and was appointed as an Associate Professor of Cancer Biology in 2001.
Speakers

In 2004 Dr. Jensen returned home to Kansas and was appointed the William R. Jewell, M.D. Distinguished Kansas Masonic Professor, the Director of The University of Kansas Cancer Center, the Director of the Kansas Masonic Cancer Research Institute, Professor of Pathology and Laboratory Medicine, and Professor of Anatomy and Cell Biology at the University of Kansas Medical Center. Since becoming director of the cancer center he has recruited a world-class leadership team and successfully led that team in achieving designation for The University of Kansas Cancer Center as a NCI-designated cancer center.

Dr. Jensen currently has over 150 scientific publications and has lectured widely on the clinical and molecular aspects of breast cancer pathology. Dr. Jensen’s research interests are focused on understanding the function of BRCA1 and BRCA2 and their role in breast and ovarian neoplasia; and in the characterization of premalignant breast disease both at the morphologic and molecular levels. His laboratory was instrumental in demonstrating the role of BRCA1 in the growth control of normal and malignant cells and in how loss of functional BRCA1 contributes to the development of breast cancer.

Michelle M. Le Beau, PhD
Director
University of Chicago Comprehensive Cancer Center

Dr. Le Beau is the Arthur and Marian Edelstein Professor of Medicine, Section of Hematology/Oncology, Director of the University of Chicago Comprehensive Cancer Center, an NCI-designated Comprehensive Cancer Center, and Director of the Cancer Cytogenetics Laboratory at the University of Chicago. Dr. Le Beau is President of the Board of Directors of the Association of American Cancer Institutes, as well as a member of the Board of Directors for AACR, and the AACR Science Policy and Government Affairs Committee. She was a member of the NIH Pathology B Study Section (1996-2001), and CAMP Study Section (2001-2006, Chair 2004-2006), as well as a member of the NCI Initial Review Group A, Cancer Centers Review Parent Committee (2005-2009). She has served on numerous editorial boards, including Blood and British Journal of Haematology, and served as Associate Editor of Genes, Chromosomes, and Cancer (1989-2005).

Dr. Le Beau has published more than 420 papers, and is an international leader in cancer cytogenetics and genetics. She is recognized for her work in identifying recurring cytogenetic abnormalities, in defining the clinical, morphological, and cytogenetic subsets of leukemia, in identifying the genetic pathways that lead to myeloid leukemias, and on the application of fluorescence in situ hybridization technology for clinical diagnostics and gene mapping. Much of her work has focused on therapy-related myeloid neoplasms. She was appointed as the cancer genetics expert for the 2008 revision of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.

Neal Lindeman, MD
Director of the Molecular Diagnostics Laboratory
Brigham and Women’s Hospital

Dr. Lindeman is the Director of the Molecular Diagnostics Laboratory at the Brigham and Women’s Hospital (BWH), Director of the Clinical Pathology Residency Training Program at BWH, Director of the Molecular Genetic Pathology Fellowship Training Program at Harvard Medical School (HMS) and Associate Professor of Pathology at HMS. He is the Chair-Elect of the Molecular Diagnostics Division of the American Association of Clinical Chemistry (AACC), past Chair of the Molecular Diagnostics Committee of the American Board of Clinical Chemistry (ABCC), and is currently involved with leadership, in differing capacities, of the Association of Clinical Laboratory Physicians and Scientists (A CLPS), Association for Molecular Pathology (AMP), and the College of American Pathologists (CAP), as well as Section Editor for Precision Medicine for the Archives of Pathology and Laboratory Medicine.

Dr. Lindeman is recognized for his work in the molecular diagnosis and molecular biology of lung cancer, beginning with the study that first reported the importance of EGFR mutations in driving the biology and predicting response to targeted therapy in lung adenocarcinoma and, most recently, in leading an international panel of experts from three organizations — CAP, AMP, and the International Association for the Study of Lung Cancer (IASLC) — in publishing guidelines for the practice of molecular testing of lung cancers.

Scott M. Lippman, MD
Director
UC San Diego Moores Cancer Center

Scott M. Lippman, MD, joined the NCI-designated comprehensive UC San Diego Moores Cancer Center as director in May 2012. He is a professor of medicine and holds the Chugai Pharmaceutical Chair in Cancer at UC San Diego and is an adjunct professor at the Salk Institute. Previously, he was chair of the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center. Dr. Lippman brings more than 25 years of experience as principal investigator of NCI translational research programs (e.g., P01s and SPORES) involving investigator-initiated clinical trials. He has participated in the national leadership of clinical/translational research planning and development within the NCI Cooperative Group setting and currently chairs an NCI study section (prevention) and sits on the National Institutes of Health Clinical Trials and Translational Research Advisory Committee (CTAC) and the CTAC Clinical Trials Planning Subcommittee. He has served on the FDA Oncologic Drugs Advisory Committee, several cancer center external advisory boards and major-trial steering committees, has played a leadership role in major American Association for Cancer Research and American Society of Clinical Oncology committees and programs,
serves on several editorial boards (e.g., Journal of the National Cancer Institute), and is editor-in-chief of the AACR journal Cancer Prevention Research.

Dr. Lippman graduated from Johns Hopkins University School of Medicine, did his internship and residency training at Johns Hopkins Hospital and Harbor-UCLA Medical Center, and had hematology/medical oncology training at Stanford University and the University of Arizona. He is triple board-certified in internal medicine, hematology and medical oncology. He has authored more than 300 publications in high-impact journals, including The New England Journal of Medicine, JAMA, PNAS, and The Lancet, and chapters in major medical textbooks. He has received many awards, among them the ASCO American Cancer Society Award, AACR Cancer Research and Prevention Foundation Award, and the ASCO Statesman Award, and he was elected to the Association of American Physicians (AAP).

Lee N. Newcomer, MD, MHA
Senior Vice President
UnitedHealthcare

Dr. Newcomer is the Senior Vice President at UnitedHealthcare (UHC) with strategic responsibility for Oncology, Genetics and Women’s Health. He began his management career as a Medical Director for CIGNA Health Care of Kansas City in 1990. From 1991 to 2000, Dr. Newcomer was the Chief Medical Officer at UHC where his work emphasized the development of performance measures and incentives to improve clinical care. Dr. Newcomer was a founding executive of Vivius, a consumer directed venture that allowed consumers to create their own personalized health plans. He returned to UHC in 2006 to focus on combining clinical, financial and administrative incentives for improved and affordable cancer care.

Dr. Newcomer is a board certified medical oncologist; he practiced medical oncology for nine years in Tulsa, Oklahoma and Minneapolis (Park Nicollet Clinic). He is the former Chairman of Park Nicollet Health Services (now HealthPartners), an integrated system of physicians and hospitals in the Minneapolis and St. Paul metropolitan area. The group is nationally recognized for its leadership in quality, safety and cost effectiveness.

Dr. Newcomer earned a BA degree from Nebraska Wesleyan University, an MD degree from the University of Nebraska College of Medicine, and a Masters of Health Administration from the University of Wisconsin at Madison. He completed his internship and residency in internal medicine at the University of Nebraska Medical Center and a fellowship in medical oncology at the Yale University School of Medicine.

Gary Palmer, MD, JD, MBA, MPH
Senior Vice President, Medical Affairs
Foundation Medicine, Inc.

Dr. Palmer is the Senior Vice President, Medical Affairs, at Foundation Medicine. He is a veteran of the pharma and biotech industry. Before Foundation Medicine, he was Vice President of Medical Affairs at Genomic Health where he directed the medical aspects of the Oncotype DX Breast Cancer Assay. After Genomic Health, he served as Chief Medical Officer of On-Q-ity, a circulating tumor cell company. Prior to Genomic Health, Dr. Palmer had extensive experience in the pharmaceutical industry, including roles as Executive Director at Kosan Bioncses and at Salmedix, Inc. where he spent time in early drug development. Previously, he spent five years at Amgen where he was involved in the development and commercialization strategies of Neulasta and Aranesp.

Before his roles in industry, Dr. Palmer served as a medical oncologist in both academia and in the community setting. Dr. Palmer was director of the Medical Breast Service at the University of California, Davis, Cancer Center and Chief of Medical Oncology at the Mercy Health System, Sacramento, California. For nine years he was on the adjunct faculty of the University of California, Davis, Graduate School of Management where he taught “Management of Biotechnology” to MBA students.

Dr. Palmer is a magna cum laude graduate of Yale University and a graduate of the Stanford University School of Medicine. He did his internal medicine training at the Boston City Hospital and his oncology fellowship at the Massachusetts General Hospital. He has a Masters in Business Administration (MBA) from the University of California, Davis, and a Masters in Public Health (MPH) from U.C.L.A. As well, Dr. Palmer holds a JD degree and is admitted as an attorney to the State Bar of California.

Dorothy E. Puhy, MBA
Executive Vice President & Chief Operating Officer
Dana-Farber Cancer Institute

Ms. Puhy is Executive Vice President and Chief Operating Officer for the Dana-Farber Cancer Institute. Previously, she served as its Chief Financial Officer and Assistant Treasurer. Prior to Dana-Farber, Ms. Puhy was the CFO for New England Medical Center Hospitals. She has also served as a healthcare consultant for the public accounting firm of Ernst & Young and as director of the Hospital Bureau for the Massachusetts Rate Setting Commission.
Ms. Puhy is Chair of the Board and Executive Committees of MASCO (Medical Academic and Scientific Community Organization, Inc.) and is a Director and Chair of the Financial Committee at CRICO (Controlled Risk Insurance Company). In addition, Ms. Puhy is a lecturer in Health Management at the Harvard School of Public Health.

Ms. Puhy earned her MBA from the Wharton School and received a BA from the University of Pennsylvania.

Scott Ramsey, MD, PhD
Full Member
Fred Hutchinson Cancer Research Center

Dr. Ramsey is a Full Member in the Cancer Prevention Program at the Fred Hutchinson Cancer Research Center where he directs the Hutchinson Institute for Cancer Outcomes Research, a multidisciplinary team devoted to clinical and economic evaluations of new and existing cancer prevention, screening and treatment technologies. He is also a Professor in the School of Medicine, School of Pharmacy, and Institute for Public Health Genetics at University of Washington. Trained in Medicine and economics, his primary research interest is in studying the economic aspects of new medical technologies. Dr. Ramsey is past President of the International Society of Pharmacoeconomics and Outcomes Research, and has served on the IOM Cancer Policy Forum.

Tony R. Reid, PhD, MD
Academic Director, Clinical Trials Office
UC San Diego Moores Cancer Center

Dr. Reid is chair of the AACI Clinical Research Initiative. He is the director of the Clinical Trials Office at UCSD, a position he has held since 2007. He received his medical degree from Stanford University, where he also received a PhD in biochemistry. Dr. Reid’s PhD thesis focused on the use of interferon to treat cancer and identified pathways involved in the anticancer effects of interferon. These studies led to the recognition that many malignancies lacked pathways that block viral infections. These observations have formed the basis for subsequent research work and clinical trials exploiting the defects in antiviral pathways in tumors to treat tumors with gene therapy vectors.

Dr. Reid was the lead investigator on the original trials using Onyx-015 to treat colorectal cancer and has pioneered the use of adenoviral and vaccinia vectors to the treatment of cancer. He has received national recognition for his work including the awards from the Interferon Society, the International Society of Gene Therapy and the Society for Interventional Radiology.

Dr. Reid has been at the forefront of using interventional radiology to selectively deliver therapeutic directly to the tumor using the tumor’s own vascular supply. Finally, Dr. Reid is on the review board of a number of journals including Nature Cancer Gene Therapy, Gene Therapy and Clinical Cancer Research.

Shaun Rosebeck, PhD
Research Fellow, Pediatric Hematology/Oncology
University of Chicago

Dr. Rosebeck is an Assistant Professor-level Research Associate at the University of Chicago Medical Center, running the research laboratory for the Director of the Multiple Myeloma Program, Andrzej J. Jakubowiak, MD PhD. Dr. Rosebeck joined the University of Chicago in the fall of 2012 as junior faculty following five years of post-doctoral training at the University of Michigan Health System, where he worked with Drs. Linda M. McAllister-Lucas and Peter C. Lucas (now affiliated with the University of Pittsburgh Medical Center).

Dr. Rosebeck’s research has focused on understanding the pathogenesis of hematologic malignancies, including a subset of lymphoma and now multiple myeloma. As part of the Multiple Myeloma Program, Dr. Rosebeck’s translational research goals are three-fold: 1) Expanding the mechanistic understanding of the biology of multiple myeloma; 2) Identifying markers of response to currently-used treatment regimens to establish predictive models of patient response toward an overall goal of personalized medicine; 3) Characterizing the mechanism of action of novel therapeutics and establish the pre-clinical feasibility of synergistic drug interactions for the treatment of both high-risk, newly-diagnosed and relapse/refractory multiple myeloma.

Kathleen Sebelius, MPA
United States Secretary of Health and Human Services

Kathleen Sebelius was sworn in as the 21st Secretary of the Department of Health and Human Services (HHS) on April 28, 2009. Since taking office, Secretary Sebelius has led ambitious efforts to improve America’s health and enhance the delivery of human services to some of the nation’s most vulnerable populations, including young children, those with disabilities, and the elderly.

As part of the historic Affordable Care Act, she is implementing reforms that have ended many of the insurance industry’s worst abuses and will help 34 million uninsured Americans get health coverage. She is also working with doctors, nurses, hospital leaders, employers, and patients to slow the growth in health care costs through better care and better health. Under Secretary Sebelius’s leadership, HHS is committed to innovation, from promoting public-private collaboration to bring
life-saving medicines to market, to building a 21st century food safety system that prevents outbreaks before they occur, to collaborating with the Department of Education, to help states increase the quality of early childhood education programs, and give parents more information to make the best choices for their children.

Secretary Sebelius served as Governor of Kansas from 2003 until her Cabinet appointment in April, 2009, and was named one of America’s Top Five Governors by Time Magazine.

Hubing Shi, PhD
Postdoctoral Fellow, Division of Dermatology
David Geffen School of Medicine at UCLA

I was born in a Chinese city famous for its pharmaceutical industry. An educational tour of some of those companies for high school students led me to choose biochemical pharmaceutics as my major in college. My grandmother’s death from cancer made me determined to alleviate suffering for people in similar circumstances.

I applied for a PhD program, led by Dr. Yongzhang Luo at Tsinghua University, which focused on cancer biology and anti-angiogenic therapy. An endogenous angiogenesis inhibitor endostatin had been identified by Dr. Michael O’Reilly of Dr. Folkman’s group, and been developed into a real drug Endostar™ by Dr. Luo. A moderate tumor response rate has been observed in Endostar treated NSCLC patient, which might be largely due to the blind-selection of patients. Some unsuitable patients whose tumors do not harbor receptors for endostatin have been applied to the therapy. To better define the potential patient population, we isolated, identified, and functionally verified nucleolin as the receptor for endostatin by an unbiased strategy (Shi et al. Blood. 2007). A diagnostic kit has been developed to detect receptor nucleolin level on tumor cell (Patent No.: EP 2375251. 2011), at the mean time a receptor-prescreen guided clinical trial has been carried out along with second generation endostatin.

My postdoctoral training included being part of a translational medical group led by Dr. Roger Lo and Antoni Ribas in 2009. By that time, a milestone event happened in the melanoma research field. A novel V600EB-RAF-specific inhibitor, named Vemurafenib, achieved an unprecedented clinical response rate, followed, however, by tumor escape from targeted inhibition. My project aimed to identify the tumor relapse mechanism and find innovative therapeutic strategies. I plan to remain focused on melanoma research as my career progresses.

Ellen V. Sigal, PhD
Chairperson and Founder
Friends of Cancer Research

Dr. Sigal is Chairperson and Founder of Friends of Cancer Research (Friends), a cancer research think tank and advocacy organization based in Washington, DC. Friends is a leader in developing partnerships and advocating for policies that will get treatments and therapies to patients in the safest and quickest way possible. Friends works with federal health agencies, Congressional leadership, academic research centers and private sector industry producing real results. Dr. Sigal is Vice Chair of the inaugural board of directors of the Reagan Udall Foundation, a partnership designed to modernize medical product development, accelerate innovation, and enhance product safety in collaboration with the U.S. Food and Drug Administration. She serves on the Board of the Foundation for the National Institutes of Health where she chairs its Public Private Partnerships Committee.

In 2010, Dr. Sigal was appointed to a six year term on the Board of Governors of the Patient Centered Outcomes Research Institute (PCORI) as a representative of patients and health consumers. She also holds leadership positions with a broad range of cancer advocacy, public policy organizations, and academic health centers including: M. D. Anderson Cancer Center External Advisory Board, the Duke University Cancer Center Board of Overseers, and Sidney Kimmel Comprehensive Cancer Center Advisory Council.

Barbara Duffy Stewart, MPH
Executive Director
Association of American Cancer Institutes

Since 1999, Barbara Duffy Stewart has served as executive director of the Association of American Cancer Institutes (AACI), comprising 95 of the leading academic and free-standing cancer research centers in the United States. Ms. Stewart oversees all administrative, financial and external affairs of the Association, and conceives and implements programs and strategies that benefit the nation’s cancer centers and contribute to the goals of the national cancer program.

Before joining AACI, Ms. Stewart was director of Communications and Public Affairs at the University of Pittsburgh Cancer Institute (UPCI). She was responsible for UPCI’s interactions with business, community, and government leaders to increase awareness of UPCI’s novel cancer programs and activities. Ms. Stewart also managed government affairs for UPCI. She was instrumental in the founding of the Pennsylvania Cancer Alliance, an association of Pennsylvania cancer centers that secured 19 percent of Pennsylvania’s tobacco settlement funds for biomedical research.
Ms. Stewart is President of the board of directors of the National Coalition for Cancer Research, Washington, DC, serves on the executive committee of Friends of Cancer Research, Washington, DC, and is a member of the Metro board of directors of the YMCA, Pittsburgh. She previously served on the board of directors of the Education Network to Advance Cancer Clinical Trials (ENACCT), the Center for Victims of Violent Crime, and Family House, Inc., where she was a member of the executive committee and chaired the public relations committee. Ms. Stewart earned a Master of Public Health degree at the University of Pittsburgh and a Bachelor of Arts degree in American Government at Georgetown University.

Jeanine Stiles
Chief Administrative Officer
Associate Director for Administration
UC Davis Comprehensive Cancer Center

Ms. Stiles is the Chief Administrative Officer and the Associate Director for Administration at the UC Davis Comprehensive Cancer Center. She joined UC Davis in February 1999 and was instrumental in helping the Cancer Center achieve NCI Designation in July 2002 and comprehensive status in 2012. Ms. Stiles’ responsibilities encompass overall strategic planning, research administration, fiscal and business management, human resources, development and administrative oversight for clinical research and patient care services. Prior to UC Davis, Ms. Stiles worked at UCLA as Contract and Grant Specialist in the Department of Microbiology and Immunology, Administrative Director for Center for AIDS Research/AIDS Clinical Trials Cooperative Group, Chief Administrative Officer for the School of Theater, Film and Television and Director of R-NET, a software development project for electronic research administration.

Ms. Stiles serves as the administrative advisor for the University of Hawaii’s Cancer Center External Advisory Board; advisor for the UC Davis Clinical and Translational Science Center; chair of the Executive Committee for the Cancer Centers Administrators Forum and conference planning committee member for the Association of American Cancer Institutes. Ms. Stiles is a board member on the Keaton Raphael Memorial Foundation for pediatric cancer.

Mary Sumpmann, MS, RN
Associate Director
Masonic Cancer Center

Ms. Sumpmann is Associate Director for Administration, Masonic Cancer Center, University of Minnesota. She is the founding associate director of administration and her responsibilities include finance, operations, facilities, outreach and communication. She is also the lead administrative liaison with the University of Minnesota Academic Health Center and the University of Minnesota Medical Center, Fairview, and has an adjunct appointment in the University of Minnesota, School of Nursing.

Ms. Sumpmann has led the Cancer Center’s administrative efforts since 1992 and participated in the development of the original proposal for the University of Minnesota Cancer Center in 1989. Ms. Sumpmann served on the Executive Committee of the Cancer Center Administrator’s Forum from 2003-2006. From 1986-1996 she also managed the University of Minnesota Hospital and Clinics (currently known as the University of Minnesota Medical Center, Fairview) Oncology Service line. During that time she was the interim administrator for both the Bone Marrow Transplantation Program and Radiation Oncology Department. In 2010 Ms. Sumpmann was named one of the School of Nursing’s 100 outstanding alumni.

W.H. van Harten MD, PhD, MPH
President
Organisation of European Cancer Institutes (OECI)

Dr. van Harten spent seven years after his graduation as an MD in tropical medicine. On returning from Cameroon, Africa he decided to focus on public health and health administration. He obtained a degree in community medicine while working as a chief medical advisor of a major health insurance company (1986-1992), and finished his PhD on quality management while serving as a chief executive officer in a rehabilitation hospital, ”Het Roessingh”, from 1992-2001, in Enschede.

In June 2001 Dr. van Harten started as a member of the executive board of the National Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL) in Amsterdam, The Netherlands, responsible for Organisation & Management. Since 2001 he has been a part-time professor at the department of Health Technology and Services Research of the School of Management and Governance at the University of Twente, the Netherlands. In 2006 he became a Board Member of the Organisation of European Cancer Centres (OECI), which dedicates itself to improve the quality of cancer care and translational research in Europe. As of June 2011 he became President of OECI for a period of three years.

Dr. van Harten’s publications are in the field of technology assessment, research into the effects of quality management and translating operations management and research techniques into hospital care.
Speakers

Michael P. Vander Hoek, MHSA
Associate Director of Administration
Georgetown Lombardi Comprehensive Cancer Center

Mr. Vander Hoek was appointed Associate Director for Administration for Georgetown Lombardi Comprehensive Cancer Center in 2007 after serving as the Center's first Chief Financial Officer starting in 2004. He works closely with Cancer Center Director Louis M. Weiner, MD, and other senior leaders to integrate his administrative leadership role into strategic, operational, and financial aspects of the Center.

Over the past 25 years, Mr. Vander Hoek has held several leadership positions within Georgetown University and MedStar Health, the Center’s clinical partner and Washington, D.C.’s largest regional health care provider. Before joining Georgetown Lombardi, he was Vice Chair of Planning and Administration for the Department of Medicine at the MedStar Georgetown University Hospital. This experience has helped him bring together the strategic visions of both institutions along with the necessary institutional resources to support the mission of the Center and to address the cancer needs of our community.

Mr. Vander Hoek earned a Master’s degree in Health Service Administration from The George Washington University. He serves on the Association of American Cancer Institutes’ Finance and Investment Committee and the Cancer Center Administrators Forum IT Steering Committee.

David VanderWeele, MD
Fellow, Department of Medicine, Section of Hematology/Oncology
The University of Chicago

Dr. VanderWeele graduated from Gordon College in Wenham, MA with a BS in biology. He obtained his MD and PhD as part of the MSTP at the University of Chicago. While there he worked with Charles Rudin on the PI3K-Akt-mTOR signaling pathway and its role in chemotherapeutic resistance. David did his residency in Internal Medicine and fellowship in the section of hematology/oncology at the University of Chicago Medicine. In the clinic he sees patients with GU malignancies. In the lab he is working with Kevin White, PhD, and Walter Stadler, MD, to learn more about the heterogeneity and evolution of prostate cancer. He recently started his new role at University of Chicago as Instructor in hematology/oncology.

Mark Velleca, MD, PhD
Chief Policy and Advocacy PhD
The Leukemia & Lymphoma Society

Dr. Velleca heads LLS’s Office of Public Policy in Washington DC. In this position, he oversees the strategy and implementation of LLS’s legislative and regulatory policy initiatives. Dr. Velleca is also responsible for patient access and advocacy, as well as patient and professional programs at LLS.

A scientist and board-certified physician, Dr. Velleca has experience in both academic research and clinical medicine as well as executive management in the private sector. He was the Founder and SVP of CGI Pharmaceuticals, guiding CGI from its inception through its establishment as a drug discovery company that brought multiple drug candidates from research into clinical trials. Gilead Sciences acquired CGI in 2010, whereupon Dr. Velleca served as a Senior Advisor at Gilead until joining LLS in 2012. He has also served on the Board of Directors and Scientific Advisory Boards of several other biotech companies.

Earlier in his career, Dr. Velleca was an attending physician at Yale-New Haven Hospital and on the clinical faculty at Yale Medical School. He earned a BS Cum Laude from Yale University and an MD and a PhD from Washington University in St. Louis. Dr. Velleca’s broad experience base in science, medicine, and drug development have provided important insights into the challenges that patients can face in gaining access to high quality, affordable health care.

Louis M. Weiner, MD
Director
Georgetown Lombardi Comprehensive Cancer Center

Dr. Weiner has been the Director of the Georgetown Lombardi Comprehensive Cancer Center since 2008 and holds the Francis L. and Charlotte G. Gragnani Chair and Professor of Oncology at Georgetown University.

Dr. Weiner earned his bachelor degree in biology with honors from the University of Pennsylvania and his medical degree from Mount Sinai School of Medicine. After completing his internship, residency, and service as chief medical resident at the University of Vermont’s Medical Center Hospital, he held clinical and research fellowships in hematology and oncology at Tufts University School of Medicine in Boston.

Prior to joining Lombardi, Dr. Weiner served as chairman of the Medical Oncology Department and vice president for Translational Research at Fox Chase Cancer Center in Philadelphia, PA. He held an endowed chair in medical science and was
the driving force behind developing an immunotherapy laboratory and clinical programs, as well as establishing the Center’s medical oncology fellowship program. Dr. Weiner also served as professor in the Department of Medicine at Temple University School of Medicine.

As Director of Lombardi, Chair of the Department of Oncology, Associate Vice President of Georgetown University Medical Center, and Clinical Director of Cancer Services at Georgetown University Hospital, Dr. Weiner is responsible for the operation and development of the cancer center, including its educational, research and clinical missions. The clinical mission includes co-chairing the Medstar-Georgetown Network in the Metropolitan Washington area. Dr. Weiner is known for his laboratory and clinical research focusing on new therapeutic approaches that mobilize the patient’s immune system to fight cancer using monoclonal antibodies and other modalities of therapy.

Scott J. Weir, PharmD, PhD
Director, Institute for Advancing Medical Innovation
University of Kansas Cancer Center

Dr. Weir is Director, Institute for Advancing Medical Innovation (IAMI), University of Kansas. IAMI conducts product development-focused translational research on products with clear paths to market. He also serves as Associate Director, Translational Research, the University of Kansas Cancer Center. Drugs, diagnostics, and medical device applications in cancer, neuroscience, rare and neglected diseases, in children and adults, are the primary focus of IAMI. Central to the translational research strategy of IAMI is establishing and executing projects through high performance collaborations with industry, academia, government and disease philanthropy organizations.

Dr. Weir has over 26 years of professional experience in the field of drug discovery and development, 20 of which were spent in the pharmaceutical industry prior to joining the University of Kansas in 2006. His specific areas of expertise are in clinical pharmacology, pharmacokinetics, biopharmaceutics, and developing innovative approaches to lead optimization and early drug development. He has built a reputation of being innovative in bridging the “Valley of Death” through high performance public-private partnerships as well as repurposing approved drugs and rescuing abandoned drugs. In 2012, Dr. Weir was appointed by HHS Secretary Kathleen Sebelius to serve on the National Center for Advancing Translational Sciences Advisory Council as well as the Cures Acceleration Network Board.

Linda K. Weiss, PhD
Director, Office of Cancer Centers
National Cancer Institute

Dr. Weiss is Director of the Office of Cancer Centers of the National Cancer Institute. Prior to joining NCI in 2000 as a program director in the Organ Systems Branch, Dr. Weiss was director and principal investigator of the SEER Program and co-director of the Epidemiology Program at the Karmanos Cancer Institute at Wayne State University. In these roles, she held responsibility for ensuring compliance with contractual program and budget requirements of NCI, state cancer reporting requirements, and privacy and confidentiality regulations; liaison activities with local hospitals, physicians, and scientists; and facilitation of research through the SEER Registry with investigators from multiple disciplines. Dr. Weiss’ research during this time period focused primarily on a long-term epidemiological study of exogenous hormone use and risk of breast cancer.

Theodore J. Yank, MHA
Dan L. Duncan Cancer Center
Baylor College of Medicine

Mr. Yank has been the Associate Director for Administration of The Dan L. Duncan Cancer Center (DLDCC) at Baylor College of Medicine (BCM) in Houston, Texas since 2004 and has coordinated BScM’s review, comment and involvement in CPRIT from its beginnings in close partnership with DLDCC and college leadership particularly BCM’s VP for Government Relations. For 14 years prior to joining BCM, Mr. Yank was on the general administrative staff of the University of Iowa Hospitals and Clinics. The Holden Comprehensive Cancer Center at UI received both NCI designation and comprehensiveness in 2000 while Mr. Yank was its administrative lead, partnered with Dr. George Weiner. He holds an MHA degree from the University of Minnesota with an emphasis in Public Affairs from the U of M’s Humphrey Institute.
Awardee Profiles

2013 Distinguished Scientist Award

Dr. Brian J. Druker  
OHSU Knight Cancer Institute

Dr. Druker is an internationally known cancer researcher who developed a drug for the treatment of chronic myeloid leukemia (CML). Dr. Druker is director and JELD-WEN chair of leukemia research at the Oregon Health and Science University Knight Cancer Institute and a Howard Hughes Medical Institute investigator.

Dr. Druker led the development of imatinib, also known as Gleevec, which is approved for use with CML, gastrointestinal stromal tumors, and other cancers. His current research is aimed at learning why a small percentage of CML patients become resistant to Gleevec and why most patients who use the drug have very low levels of cancer that linger, even after successful treatment. His laboratory is also working to identify the molecular defects that drive the growth of other leukemias and to develop new, targeted treatments to improve outcomes for patients with these leukemias.

Dr. Druker is a recipient of the 2009 Lasker-DeBakey Award. Other career milestones include becoming a member of the National Academy of Sciences in 2007, winning the Japan Award in 2011 and being elected to the American Academy of Arts and Sciences in 2012. He is the recipient of a Lifetime Achievement Award from the Leukemia and Lymphoma Society, the Medal of Honor from the American Cancer Society, and many other awards.

The AACI Distinguished Scientist Award acknowledges extraordinary scientific accomplishments and contributions to cancer research. Previous honorees are Lee Hartwell, Mary Claire King, Janet Rowley, Stuart Schreiber, Margaret R. Spitz, Bert Vogelstein, Robert Weinberg and Irving Weissman.

2013 AACI Distinguished Public Service Awards

The Honorable Lois Capps  
United States House of Representatives

AACI recognizes U.S. Representative Lois Capps (D-CA) with its 2013 Distinguished Public Service Award for her outstanding efforts on behalf of cancer patients and medical research.

Congresswoman Capps serves as co-chair of the House Cancer Caucus and founded and co-chairs the House Nursing Caucus. In 2000, Capps’ daughter, Lisa Margarit Capps, died after a year-long battle against lung cancer. The congresswoman has been a passionate voice on lung cancer prevention, playing a substantive role in passage of the Family Smoking Prevention and Tobacco Control Act. She has sponsored and co-sponsored many bills on health care and cancer and served on various health and cancer-related committees and caucuses.

The Honorable Peter T. King  
United States House of Representatives

AACI recognizes U.S. Representative Peter T. King (R-NY) with its 2013 Distinguished Public Service Award for his outstanding record of support for biomedical research.

Congressman King is serving his eleventh term in the U.S. House of Representatives. He is a strong supporter of funding to combat deadly illnesses such as breast cancer and prostate cancer and serves as a member of the House Cancer Caucus. He also has been a dedicated and effective leader in the war against breast cancer throughout his years in Congress. Rep. King has supported legislation to increase Medicare reimbursements for screening and diagnostic mammographies; fund research centers to study the relationship between the environment and breast cancer; and require insurance companies to guarantee at least 48 hours hospital care after a mastectomy.
Exhibitors

The American Association for Cancer Research and the Association of American Cancer Institutes express appreciation to the following companies for their support of this educational activity by providing exhibit fees:

**iLab Solutions, LLC**
iLab Solutions is the leading provider of core facility management solutions to academic research institutions. In March 2013 iLab signed a partnership with Vanderbilt University CORES. This partnership brings together the two most sophisticated and broadly-used solutions for core facility management serving almost 1,000 core facilities across more than 85 research institutions, including 30 of the top 50 recipients of NIH funding and 24 NCI-designated cancer centers. iLab has extensive experience providing enterprise-level solutions. These solutions include institutional financial systems (e.g., SAP, Oracle, PeopleSoft, Lawson, Banner, IFAS, etc.) and identity management systems (e.g., Active Directory, Shibboleth, etc.).

**Intellisphere**
Intellisphere is a leading provider of healthcare publishing, research, information, and education for the medical industry. Our company serves the needs of hundreds of thousands of general practitioners, specialists, nurses, pharmacists, and managed care professionals through an extensive suite of magazines, journals, e-mail databases, websites, events, and personal meetings. We strive to inform and educate oncology professionals with the latest clinically relevant news and insights through our OncLive® publications and website. Through our new Strategic Alliance Partnership program, we are able to promote the research innovation and outreach programs of the leading cancer centers and oncology nursing programs across the country. The partnerships provide our audience of community oncologists with direct access to important research, clinical trial initiatives and clinical practice news that are ongoing at these institutions.

**Virtify**
Virtify is the industry leader in providing clinical trial disclosure software and services to academic and research institutions. More research organizations rely on Virtify for their registration and reporting to ClinicalTrials.gov than any other company. Our Virtify™ CTRR software (Clinical Trials Registration & Results) provides intuitive automation and tracking capabilities, including enabling clients to automatically gather required trial information from clinical trial management systems and analysis tools such as SAS® and Excel® without the need for manual re-entry of data from those systems. For example, Virtify has partnered with Forte Research to directly integrate with the OnCore® CTMS system. Virtify CTRR helps users significantly reduce the time and effort needed to achieve and maintain compliance with FDA laws governing disclosure of trial information to the public thus lowering costs and minimizing the risks associated with non-compliance.

Support

**Acknowledgment of Commercial Support**
The American Association for Cancer Research and the Association of American Cancer Institutes express appreciation to the following companies for their support of this educational activity by providing an unrestricted educational grant:

- Amgen
- Astellas
- Genentech
- Genomic Health
- Huron Consulting Group
- Pfizer

**Acknowledgment of Programmatic Support**
The Association of American Cancer Institutes gratefully acknowledges the following organizations for providing program and activity support:

- Amgen
- Astellas
- Bristol-Myers Squibb
- Celgene
- Essex Management
- Genentech
- Gilead
- Lilly
- United States Diagnostic Standards
- Velos
- Virtify
Disclosure of Financial Relationships

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

Relationships are abbreviated as follows: E, Employee of listed company; G, Grant/research support recipient; A, Advisor or review panel member; C, Consultant; S, Stock Shareholder; SB, Speakers’ Bureau; H, Honoraria; O, Other.

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abrams</td>
<td>Jeffrey</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>An</td>
<td>Lawrence</td>
<td>University of Michigan Comprehensive Cancer Center</td>
</tr>
<tr>
<td>Anderson</td>
<td>Elizabeth</td>
<td>OHSU Knight Cancer Institute</td>
</tr>
<tr>
<td>Arzoumanian</td>
<td>Rhoda</td>
<td>Carbone Cancer Center, University of Wisconsin, Madison</td>
</tr>
<tr>
<td>Austin</td>
<td>Christopher</td>
<td>National Center for Advancing Translational Sciences</td>
</tr>
<tr>
<td>Bach</td>
<td>Peter</td>
<td>Memorial Sloan-Kettering Cancer Center</td>
</tr>
<tr>
<td>Benedict</td>
<td>Michael</td>
<td>Georgia Regents University</td>
</tr>
<tr>
<td>Brito</td>
<td>Brenda</td>
<td>Medical College of Wisconsin</td>
</tr>
<tr>
<td>Brown</td>
<td>Andrea</td>
<td>Blood Research Institute, BloodCenter of Wisconsin</td>
</tr>
<tr>
<td>Burroughs</td>
<td>Katherine</td>
<td>Association of American Cancer Institutes</td>
</tr>
<tr>
<td>Curran</td>
<td>Walter</td>
<td>Winship Cancer Institute of Emory University</td>
</tr>
<tr>
<td>Damiani</td>
<td>Lisa</td>
<td>Roswell Park Cancer Institute</td>
</tr>
<tr>
<td>deVere White</td>
<td>Ralph</td>
<td>UC Davis Comprehensive Cancer Center</td>
</tr>
<tr>
<td>DiPaola</td>
<td>Rob</td>
<td>The Cancer Institute of New Jersey, Robert Wood Johnson Medical School</td>
</tr>
<tr>
<td>Druker</td>
<td>Brian</td>
<td>OHSU Knight Cancer Institute</td>
</tr>
<tr>
<td>Ellis</td>
<td>Chad</td>
<td>Yale Cancer Center, Yale University School of Medicine</td>
</tr>
<tr>
<td>Emanuel</td>
<td>Ezekiel</td>
<td>University of Pennsylvania</td>
</tr>
<tr>
<td>Erickson</td>
<td>Kristen</td>
<td>University of Kansas Cancer Center</td>
</tr>
<tr>
<td>Gallagher</td>
<td>Colleen</td>
<td>MD Anderson Cancer Center</td>
</tr>
<tr>
<td>Gerson</td>
<td>Stanton</td>
<td>Case Comprehensive Cancer Center, Case Western Reserve University</td>
</tr>
<tr>
<td>Goldstein</td>
<td>Ted</td>
<td>University of California, Santa Cruz</td>
</tr>
<tr>
<td>Goodman</td>
<td>Ira</td>
<td>UC San Diego Moores Cancer Center</td>
</tr>
<tr>
<td>Gray</td>
<td>Shirley</td>
<td>Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences</td>
</tr>
<tr>
<td>Gruber</td>
<td>Steve</td>
<td>USC/Norris Comprehensive Cancer Center, University of Southern California</td>
</tr>
<tr>
<td>Hart</td>
<td>William</td>
<td>Jensen Research &amp; Development, LLC</td>
</tr>
<tr>
<td>Hess</td>
<td>Jay</td>
<td>University of Michigan Comprehensive Cancer Center</td>
</tr>
<tr>
<td>Holcombe</td>
<td>Randall</td>
<td>Tisch Cancer Institute</td>
</tr>
<tr>
<td>Jacques</td>
<td>Louis</td>
<td>Centers for Medicare &amp; Medicaid Services</td>
</tr>
<tr>
<td>Jensen</td>
<td>Roy</td>
<td>University of Kansas Cancer Center</td>
</tr>
<tr>
<td>LeBeau</td>
<td>Michelle</td>
<td>University of Chicago Comprehensive Cancer Center</td>
</tr>
<tr>
<td>Linderman</td>
<td>Neal</td>
<td>Brigham and Women’s Hospital</td>
</tr>
<tr>
<td>Lippman</td>
<td>Scott</td>
<td>UC San Diego Moores Cancer Center</td>
</tr>
<tr>
<td>Newcomer</td>
<td>Lee</td>
<td>UnitedHealthcare</td>
</tr>
<tr>
<td>Palmer</td>
<td>Gary</td>
<td>Foundation Medicine, Inc.</td>
</tr>
<tr>
<td>Ramsey</td>
<td>Scott</td>
<td>Fred Hutchinson Cancer Research Center</td>
</tr>
<tr>
<td>Reid</td>
<td>Tony</td>
<td>UC San Diego Moores Cancer Center</td>
</tr>
<tr>
<td>Seballos</td>
<td>Kathleen</td>
<td>United States Department of Health and Human Services</td>
</tr>
<tr>
<td>Sigal</td>
<td>Ellen</td>
<td>Friends of Cancer Research</td>
</tr>
<tr>
<td>Stewart</td>
<td>Barbara Duffy</td>
<td>Association of American Cancer Institutes</td>
</tr>
<tr>
<td>Stiles</td>
<td>Jeannine</td>
<td>UC Davis Comprehensive Cancer Center, The University of California, Davis Medical Center</td>
</tr>
<tr>
<td>Sumpmann</td>
<td>Mary</td>
<td>Masonic Cancer Center</td>
</tr>
<tr>
<td>Tidball</td>
<td>Jacques</td>
<td>UCI Chao Family Comprehensive Cancer Center, University of California Irvine</td>
</tr>
<tr>
<td>Vance</td>
<td>Barbara</td>
<td>NYU Cancer Institute</td>
</tr>
<tr>
<td>VanderHoeck</td>
<td>Michael</td>
<td>Lombardi Comprehensive Cancer Center at Georgetown University</td>
</tr>
<tr>
<td>van Harten</td>
<td>Wim</td>
<td>Universit Ziekenhuis Brussel</td>
</tr>
<tr>
<td>Velche</td>
<td>Mark</td>
<td>Leukemia and Lymphoma Society</td>
</tr>
<tr>
<td>Weiner</td>
<td>Louis</td>
<td>Lombardi Comprehensive Cancer Center at Georgetown University</td>
</tr>
<tr>
<td>Weir</td>
<td>Scott</td>
<td>University of Kansas Cancer Center</td>
</tr>
<tr>
<td>Weiss</td>
<td>Linda</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>Willman</td>
<td>Cheryl</td>
<td>University of New Mexico Cancer Center</td>
</tr>
<tr>
<td>Yank</td>
<td>Ted</td>
<td>Dan L. Duncan Cancer Center, Baylor College of Medicine</td>
</tr>
</tbody>
</table>

Relationships Type, Role:
- No Relationships
- Speaker
- Program Committee
- Employee of listed company
- Grant/research support recipient
- Advisor or review panel member
- Consultant
- Stock Shareholder
- Speakers’ Bureau
- Honoraria
- Other.